Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-287-1 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Secondary citation data on toxicokinetics of the component barium chromate (CAS 10294-40-3):
- In female ICR mice exposed head-only over 30 min to airborne 51Cr-labelled barium chromate, 26% of the dose initially deposited in the lungs, 4.6% in rest of the body, and absorption from the lungs was calculated as 15% i.e. poorer than for sodium chromate (51%) and calcium chromate (43%).
- In rats exposed whole-body to barium chromate dust for 15 months, it mainly accumulated in lung tissue, with some evidence of absorption and distribution to tissues with elevated Cr levels (liver, kidney, spleen, brain, salivary gland, testes, skin and bone).
- In mice, intratracheal administration led to very slow elimination with >80% of the dose remaining in lung at 48h. Excretion was more fecal than urinary.
Secondary citation data on toxicokinetics of chromium VI without precision:
Absorption:
- Oral absorption is poor, as confirmed in humans, possibly due to reduction into CrIII by stomacal acidity.
- Dermal absorption is limited, at most 4% of applied dose for water-soluble CrVI compounds (unlike barium chromate)
Distribution:
- Rapidly distributes to red blood cells because of a specific anion transporter in cell membrane. Afterwards, spleen Cr levels can increase over several weeks due to red blood cell sequestration.
- Most of it is bound irreversibly to hemoglobin.
- Soluble CrVI can cross the placenta and reach the embryo.
Metabolism:
- Reduced into CrIII in plasma (preventing its uptake under this form) by glutathione, ascorbic acid, cysteine or micromosial p450 enzymes
Secondary source data: review:
Cross HJ, Faux SP, Sadhra S et al. Criteria Document for Hexavalent Chromium. International Chromium Development Association. April 1997.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
